Age and Sex Trends in Long-term Opioid Use in Two Large American Health Systems Between 2000 and 2005
Version of Record online: 25 NOV 2009
© American Academy of Pain Medicine
Volume 11, Issue 2, pages 248–256, February 2010
How to Cite
Thielke, S. M., Simoni-Wastila, L., Edlund, M. J., DeVries, A., Martin, B. C., Braden, J. B., Fan, M.-Y. and Sullivan, M. D. (2010), Age and Sex Trends in Long-term Opioid Use in Two Large American Health Systems Between 2000 and 2005. Pain Medicine, 11: 248–256. doi: 10.1111/j.1526-4637.2009.00740.x
- Issue online: 26 JAN 2010
- Version of Record online: 25 NOV 2009
- Chronic Pain;
Objective. To estimate recent age- and sex-specific changes in long-term opioid prescription among patients with chronic pain in two large American Health Systems.
Design. Analysis of administrative pharmacy data to calculate changes in prevalence of long-term opioid prescription (90 days or more during a calendar year) from 2000 to 2005, within groups based on sex and age (18–44, 45–64, and 65 years and older). Separate analyses were conducted for patients with and without a diagnosis of a mood disorder or anxiety disorder. Changes in mean dose between 2000 and 2005 were estimated, as were changes in the rate of prescription for different opioid types (short-acting, long-acting, and non-Schedule 2).
Patients. Enrollees in HealthCore (N = 2,716,163 in 2000) and Arkansas Medicaid (N = 115,914 in 2000).
Results. Within each of the age and sex groups, less than 10% of patients with a chronic pain diagnosis in HealthCore, and less than 33% in Arkansas Medicaid, received long-term opioid prescriptions. All age, sex, and anxiety/depression groups showed similar and statistically significant increases in long-term opioid prescription between 2000 and 2005 (35–50% increase). Per-patient daily doses did not increase.
Conclusions. No one group showed especially large increases in long-term opioid prescriptions between 2000 and 2005. These results argue against a recent epidemic of opioid prescribing. These trends may result from increased attention to pain in clinical settings, policy or economic changes, or provider and patient openness to opioid therapy. The risks and benefits to patients of these changes are not yet established.